## Malaria Prophylaxis Failure and Relapse Epidemiology ### Clinical Scenario Analysis **Key Point:** The patient took chloroquine during her stay in Chhattisgarh but did NOT complete the post-travel course. She presents 6 weeks after return with P. vivax parasitaemia — this timeline and incomplete prophylaxis regimen point to **relapse from hypnozoites**, not primary infection failure. ### Hypnozoite Biology and Relapse Patterns **High-Yield:** P. vivax and P. ovale possess hypnozoites (dormant liver forms) that: - Persist in hepatocytes despite adequate blood-stage schizonticide therapy (chloroquine) - Can activate weeks to months (even years) after the primary infection - Cause clinical relapses in ~50% of untreated cases and ~10–15% of chloroquine-treated cases - Require primaquine (an 8-aminoquinoline) for true radical cure ### Why Chloroquine Alone Failed | Drug | Blood-stage schizont | Hypnozoite | Gametocyte | |------|----------------------|------------|------------| | Chloroquine | ✓ Effective | ✗ Inactive | ✓ Partial | | Primaquine | ✗ Inactive | ✓ Effective | ✗ Inactive | | Artemisinin derivatives | ✓ Effective | ✗ Inactive | ✓ Effective | **Clinical Pearl:** Chloroquine is a blood schizonticide and suppresses clinical symptoms, but does NOT eradicate hypnozoites. Without primaquine, relapses are inevitable in P. vivax and P. ovale infections. The patient's incomplete post-travel primaquine course (which should have been given after chloroquine) left her vulnerable to relapse. ### Timeline Interpretation - **During stay (Chhattisgarh):** Acquired P. vivax infection; took chloroquine → cleared blood parasites, but hypnozoites persisted in liver - **Post-travel (6 weeks later):** Hypnozoites activated → clinical relapse with parasitaemia - **Presentation:** Fever, myalgia, parasites on blood smear — consistent with relapse, not new infection ### Epidemiological Significance **Mnemonic:** **CHAP** — Chloroquine-treated Hypnozoite-containing infections need Primaquine for Adequate eradication. Relapse is a major epidemiological challenge in P. vivax control because: 1. Patients may not seek care for relapses (milder than primary attack) 2. Untreated relapses serve as reservoirs for continued transmission 3. Incomplete prophylaxis regimens (missing primaquine) perpetuate the problem --- ## Distractor Analysis **Option 0 — "Urban vector A. stephensi during return journey":** A. stephensi is found in urban/semi-urban areas but is not the primary vector in Chhattisgarh (A. culicifacies is endemic there). More importantly, the 6-week delay between return and symptom onset is inconsistent with a new infection acquired during travel (P. vivax incubation is typically 10–14 days). This option confuses vector geography and ignores the clinical timeline. **Option 2 — "Chloroquine-resistant P. vivax":** While chloroquine resistance in P. vivax has been reported in some regions (Southeast Asia, Papua New Guinea), it is NOT endemic to Chhattisgarh, India. Moreover, chloroquine resistance would present as parasitaemia during prophylaxis, not 6 weeks after stopping it. This option invokes a non-endemic resistance pattern. **Option 3 — "Blood transfusion at pre-travel check-up":** Transfusion-transmitted malaria is rare in India due to blood bank screening protocols. The clinical presentation and timeline (6 weeks post-return, not immediately after transfusion) do not fit transfusion-transmitted malaria. This is an epidemiologically implausible distractor.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.